Optimising Multi-stakeholder Practices in Patient Engagement: A Gap Analysis to Enable Focused Evolution of Patient Engagement in the Development and Lifecycle Management of Medicines.

Gap analysis Medicine research and development Medicines lifecycle Patient engagement Practices Processes

Journal

Therapeutic innovation & regulatory science
ISSN: 2168-4804
Titre abrégé: Ther Innov Regul Sci
Pays: Switzerland
ID NLM: 101597411

Informations de publication

Date de publication:
11 2021
Historique:
received: 23 09 2020
accepted: 07 06 2021
pubmed: 29 6 2021
medline: 16 10 2021
entrez: 28 6 2021
Statut: ppublish

Résumé

The PARADIGM consortium aimed to make patient engagement in the development and lifecycle management of medicines easier and more effective for all, with the development of new tools that fulfil robustly defined gaps where engagement is suboptimal. To generate an inventory of gaps in patient engagement practices and process from existing global examples. A large set of criteria for effective patient engagement previously defined via a multi-stakeholder Delphi method, were mapped under fourteen overarching themes. A gap analysis was then performed by twenty-seven reviewers against the resulting forty-six mapped criteria, on a sample of seventy initiatives from global databases. An inventory of gaps was identified including contextual information as to why the gaps exist. Our work identified general patterns where patient engagement was suboptimal-defined as; fragmented reporting and dissemination of patient engagement activities, and the fundamental principles defined in frameworks or guidance being poorly adhered to in actual practice. Specific gaps were identified for sixteen criteria. Additionally, it was also common to observe primary aspects of a process were addressed for a given criteria (i.e. training for roles and responsibilities) but a secondary context element was lacking (i.e. making training material accessible/understandable/meaningful to all participants). The results show that the evolution towards meaningful and systematic patient engagement is occurring, yet more importantly they provide clear directional insights to help enhance collaborative practices and co-design solutions. This targeted impact to catalyse a needs-oriented health system that integrates patient engagement at its core is essential.

Sections du résumé

BACKGROUND
The PARADIGM consortium aimed to make patient engagement in the development and lifecycle management of medicines easier and more effective for all, with the development of new tools that fulfil robustly defined gaps where engagement is suboptimal.
AIMS
To generate an inventory of gaps in patient engagement practices and process from existing global examples.
METHODS
A large set of criteria for effective patient engagement previously defined via a multi-stakeholder Delphi method, were mapped under fourteen overarching themes. A gap analysis was then performed by twenty-seven reviewers against the resulting forty-six mapped criteria, on a sample of seventy initiatives from global databases.
RESULTS
An inventory of gaps was identified including contextual information as to why the gaps exist. Our work identified general patterns where patient engagement was suboptimal-defined as; fragmented reporting and dissemination of patient engagement activities, and the fundamental principles defined in frameworks or guidance being poorly adhered to in actual practice. Specific gaps were identified for sixteen criteria. Additionally, it was also common to observe primary aspects of a process were addressed for a given criteria (i.e. training for roles and responsibilities) but a secondary context element was lacking (i.e. making training material accessible/understandable/meaningful to all participants).
CONCLUSION
The results show that the evolution towards meaningful and systematic patient engagement is occurring, yet more importantly they provide clear directional insights to help enhance collaborative practices and co-design solutions. This targeted impact to catalyse a needs-oriented health system that integrates patient engagement at its core is essential.

Identifiants

pubmed: 34181236
doi: 10.1007/s43441-021-00313-9
pii: 10.1007/s43441-021-00313-9
pmc: PMC8492561
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1165-1179

Informations de copyright

© 2021. The Author(s).

Références

Ther Innov Regul Sci. 2018 Mar;52(2):220-229
pubmed: 29714515
Health Expect. 2019 Aug;22(4):785-801
pubmed: 31012259
BMJ Innov. 2019 Jan;5(1):43-55
pubmed: 31645992
Health Policy. 2012 Oct;107(2-3):231-42
pubmed: 22739128
Health Expect. 2020 Jun;23(3):691-706
pubmed: 32181553
Ther Innov Regul Sci. 2017 Sep;51(5):612-619
pubmed: 30231692
Ther Innov Regul Sci. 2015 Nov;49(6):929-939
pubmed: 26539338
Ther Innov Regul Sci. 2017 Jan;51(1):29-38
pubmed: 28232876
Soc Sci Med. 2005 Jun;60(11):2575-84
pubmed: 15814182
Health Expect. 2020 Feb;23(1):5-18
pubmed: 31489988
Ther Innov Regul Sci. 2015 Jan;49(1):9-16
pubmed: 30222454
Health Expect. 2015 Oct;18(5):1397-412
pubmed: 23992108
Curr Opin Psychiatry. 2019 Nov;32(6):557-562
pubmed: 31306247
Res Involv Engagem. 2018 May 22;4:17
pubmed: 29796308
Health Expect. 2005 Sep;8(3):253-63
pubmed: 16098155
Pharmaceut Med. 2019 Jun;33(3):179-185
pubmed: 31933291
Health Expect. 2018 Feb;21(1):75-81
pubmed: 28752577
Ann Oncol. 2011 Nov;22 Suppl 7:vii54-vii56
pubmed: 22039147

Auteurs

S D Faulkner (SD)

Radcliffe Primary Care Building, Radcliffe Observatory Quarter, Woodstock Rd, Oxford, OX2 6GG, UK. stuart.faulkner@phc.ox.ac.uk.

C A C M Pittens (CACM)

Athena Institute for Health and Life Science, Vrije Universiteit Amsterdam, De Boelelaan 1085, 1081 HV, Amsterdam, The Netherlands.

N S Goedhart (NS)

Athena Institute for Health and Life Science, Vrije Universiteit Amsterdam, De Boelelaan 1085, 1081 HV, Amsterdam, The Netherlands.

E H Davies (EH)

Radcliffe Primary Care Building, Radcliffe Observatory Quarter, Woodstock Rd, Oxford, OX2 6GG, UK.
Aparito, Unit 11-12 Gwenfro, Wrexham Technology Park, Wrexham, LL13 7YP, WAL, UK.

E Manning (E)

UCB Pharma, 8010 Arco Corporate Drive, Raleigh, NC, 27617, USA.

A Diaz-Ponce (A)

Alzheimer Europe, 14 Rue Dicks, 1417, Luxembourg, Luxembourg.

Maria Jose Vicente Edo (M)

Aragon Health Sciences Institute, Instituto Aragones de Ciencias de La Salud (IACS), Zaragoza, Spain.

L Prieto-Remón (L)

Aragon Health Sciences Institute, Instituto Aragones de Ciencias de La Salud (IACS), Zaragoza, Spain.

L Husain (L)

Radcliffe Primary Care Building, Radcliffe Observatory Quarter, Woodstock Rd, Oxford, OX2 6GG, UK.

K Huberman (K)

European AIDS Treatment Group, Av des Arts 56-4c, 1000, Brussels, Belgium.

M Boudes (M)

European Patients' Forum, Chaussée d'Etterbeek 180, Brussels, Belgium.

M Subramaniam (M)

Bayer AG. Medical Affairs & Pharmacovigilance, Mullerstrasse 178, 13353, Berlin, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH